skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

In the EU a rare disease is defined as one with a prevalence of 1 in 2,000 people, and in the US, as affecting fewer than 200,000 people (equivalent to 1 in 1,600 people as of 2013 population figures).

In this report, we will focus on rare diseases defined as per above. By these definitions, there are between 6,000 and 8,000 recognised rare diseases, most of them arising from genetic origin and being chronic or life-threatening.

Highlights in this white paper include:

With the ‘blockbuster bubble’ seemingly burst and patent protection giving way to huge rises in generic competition, the pharma industry appears to be focusing on high value drugs for rare diseases of low prevalence for which there is a potential for rich return on investment.
Using Citeline data, this paper analyzes the landscape for rare diseases and the density of development by phase, developing company and disease.

 

  • The number and prevalence of rare diseases in the US and EU
  • The number of drugs in active development by phase and the
    companies developing them
  • Areas of therapeutic focus for rare disease development
  • Drugs and vaccines in development for infectious diseases 
  • The oncology landscape for rare diseases, and which drugs
    are exhibiting the most promise



Will the Blockbuster Model be Replaced

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: